Li Lanjuan

[Expert Profile] Li Lanjuan, Chief Physician, Professor, Doctoral Supervisor, Academician of the Chinese Academy of Engineering, is an authoritative expert in infectious diseases in China, working at Shulan (Hangzhou) Hospital. She has long been dedicated to clinical diagnosis, treatment, and scientific research of severe infections, drug-resistant infections, and difficult infectious diseases, and is an important leading figure in infectious diseases and microecology both domestically and internationally.

[Education & Career] Professor Li Lanjuan graduated from Zhejiang Medical University, completed systematic clinical training at the First Affiliated Hospital of Zhejiang University School of Medicine, and further studied at famous international infectious disease centers. She has long served as Director of the Department of Infectious Diseases at the First Affiliated Hospital of Zhejiang University and Director of the State Key Laboratory for Diagnosis and Treatment of Infectious Diseases. She was elected as an Academician of the Chinese Academy of Engineering in 2005, and has held important academic positions including Chair of the Infectious Diseases Branch of the Chinese Medical Association. She is an academic leader in the field of infectious diseases in China.

[Areas of Expertise] Professor Li specializes in the diagnosis and treatment of severe infections, drug-resistant bacterial infections, difficult infectious diseases, and severe hepatitis with liver failure. She has profound expertise in artificial liver support system (Li's Artificial Liver) treatment of liver failure, microecological regulation and infection prevention, and precise treatment of drug-resistant bacterial infections. She excels at managing critical infection cases of "multiple organ failure and rampant drug-resistant bacteria," helping numerous critical patients turn the corner.

[Academic Achievements & Industry Contributions] The "Li's Artificial Liver" support system pioneered by Professor Li has significantly reduced the mortality rate of severe hepatitis with liver failure, and has been widely promoted and applied domestically and internationally. She has systematically conducted research on infection microecology, elucidating the mechanism of gut microbiota in infection and liver disease, with findings published in top international journals. She has repeatedly participated in prevention, control, and treatment efforts for major infectious disease outbreaks (including H7N9 avian influenza, COVID-19, etc.), serving as a core member of national expert panels. Treatment strategies she proposed such as "four antagonisms and two balances" have saved countless patient lives, making outstanding contributions to infectious disease prevention and control in China and globally.

[Clinical Practice & Outstanding Contributions] For decades on the front lines of infectious disease clinical work, Professor Li has treated tens of thousands of patients with various infections and liver diseases, leading her team in successfully managing numerous critical infection and liver failure patients. She has received multiple national awards including the Special Prize of the National Science and Technology Progress Award, and has been repeatedly recognized as a national outstanding Communist Party member and national advanced worker. She has trained a large number of infectious disease leaders, and is a truly deserving authority in the field of infectious diseases in China, deeply admired by patients and peers alike.

[Honors & Reputation] Professor Li Lanjuan serves as Director of the State Key Laboratory for Diagnosis and Treatment of Infectious Diseases and Chair of the Infectious Diseases Branch of the Chinese Medical Association, among other academic positions. She was elected as an Academician of the Chinese Academy of Engineering in 2005, has presided over national-level major projects including the National "973" Program and Key R&D Program, and is an authoritative expert in the field of infectious diseases in China. The "Li's Artificial Liver" support system she pioneered has significantly reduced the mortality rate of severe hepatitis with liver failure, and has been widely promoted and applied domestically and internationally. In major outbreaks such as H7N9 avian influenza and COVID-19, she served as a core member of national expert panels, and treatment strategies she proposed such as "four antagonisms and two balances" have saved countless patient lives. She has received multiple national awards including the Special Prize of the National Science and Technology Progress Award, trained a large number of infectious disease leaders, and is a pillar of the field of infectious diseases in China.